Objectives: To present the effect of intravitreal ranibizumab (IVR) therapy combined with sulfotanshinone sodium (SS) injection in a patient suffering from type II optic disc vasculitis (ODV). Methods: A 26-year-old female patient was diagnosed with type II ODV with macular edema (ME). The information was obtained by complete medical and ophthalmic history taking and a detailed ophthalmic examination at the initial and follow-up visits. Functional and morphological outcomes at baseline, 1 week and 1 month following IVR+SS injections, are presented. Results: Bestcorrected visual acuity (BCVA) improved from 78 letters (ETDRS) at baseline to 90 letters at 1-week follow-up and maintained stable through 1-month follow-up. Central retinal thickness (CRT) measured by optical coherence tomography (OCT) decreased from 465 μm at baseline to 240 μm at 1-week follow-up and to 226 μm at 1-month follow-up. Mean deviation (MD) measured by perimetry increased from −5.17 dB to −4.59 dB and to −4.29 dB, respectively. Fluorescein angiography (FFA) showed that the initial macular edema at baseline disappeared while the arm-retina circulation time (ART) was also greatly shortened when compared to the baseline. Electroretinogram (ERG) measured at 1-month follow-up demonstrated an overall improvement of the retinal function after the injection. No ocular or systemic side effects were detected. Conclusions: IVR+SS injection may lead to resolution of the associated ME and improve the retina morphologically as well as functionally. To our knowledge, this is the first case of a type II ODV benefiting from treatment with IVR+SS injection. The observed results warrant further investigation.
Introduction
Optic disc vasculitis (ODV) is an uncommon, chronic and self-limiting disorder characterized by unilateral optic disc swelling and minimal visual symptoms, seen mostly in young adults with no gender predilection [1] [2] . Type II ODV is considered to result from phlebitis of the central retinal venous in the region of the optic nerve head or retro-laminar region and is usually misdiagnosed as central retinal venous occlusion (CRVO) because they share quite similar clinical pictures.
This 26-year-old female patient presented with obvious ME, exudation and hemorrhage with no big improvement after hormone therapy. Considering the similarities between these two diseases, we intended to apply our previous clinical experience in treating RVO patients on this patient.
Intravitreal injections of ranibizumab have been shown to be an effective treatment option for RVO patients [3] [4] [5] . Our previous studies have also demonstrated the therapeutic effect of SS injections in treating RVO patients [6] [7] [8] . This case study was designed to assess the efficacy and safety of IVR+SS infection in treating this type II ODV patient.
Materials and Methods
The information was obtained by complete medical and ophthalmic history taking and a detailed ophthalmic examination at the initial and follow-up visits.
Best-corrected visual acuity (BCVA) was 100 letters (ETDRS) OD and 78 letters OS This 26-year-old female patient was treated with one IVR injection combined with SS injections (20 mg per day, five days consecutively in one week, 4 weeks). Written consent for the use of IVR therapy was obtained from the patient and a Ranibizuman (0.5 mg in 0.05 ml) (Lucentis, Genentech Inc.) was applied to the patient's left eye. SS injection (5 mg/ml) (batch number: H120921) manufactured by the First Biochemical Pharmaceutical Co. Ltd., Shanghai, China, is approved by State Food and Drug Administration of China. SS injection was given diluted at the point of treatment in 250 ml 5% glucose injection for intravenous administration.
In addition to the treatment medicines, usages of any other traditional Chinese medicine or Western medicine were prohibited.
Except that FFA and ERG were done at one-month follow up, other examinations were repeated at one-week and one-month follow up.
Results
At 1 week following the IVR+SS injection, BCVA improved from 78 letters (ETDRS) at baseline to 90 letters at 1-week follow-up and maintained stable through 1-month follow-up. The CRT measured by OCT decreased from 465 μm at baseline to 240 μm at 1-week follow-up and to 226 μm at 1-month follow-up. Mean deviation (MD) measured by perimetry increased from −5.17 dB to −4.59 dB and to −4.29 dB, respectively ( Table 1) . Retinal hemorrhage was reduced significantly demonstrated by the fundus examination and the macular edema had completely resolved as demonstrated by OCT through the 1-month follow-up (Figures 1-3) . The arm-retina circulation time (ART) was also greatly shortened when compared to the baseline. ERG results showed an overall improvement of the retinal function as compared to the baseline (Table 2) . IOP was measured unchanged at 15 mmHg under given local therapy. No ocular or systemic side effects were detected. 
Discussion
Optic disc vasculitis (ODV) is an uncommon, chronic and self-limiting disorder characterized by unilateral optic disc swelling and minimal visual symptoms, seen mostly in young adults with no gender predilection [1] . Hayreh first described this clinical entity in 1972 [2] . Based on the clinical findings of optic disc and peripheral retinal hemorrhages, he subdivided his patients into two groups (type I and type II). Type I may result from mild non-specific vasculitis of the ciliary vessel in the prelaminar region. Danshen dripping pills could be a promising method for the treatment of ischemic retinal disorders through reducing oxidative stress [6] . Our previous clinical study has demonstrated that SS injection was an effective and safe modality for treating RVO patients [7] . We also have shown that IVR injection and SS injection together could effectively improve the therapeutic effect in RVO patients with ME [8] . Therefore, we treated this patient with one intravitreal injection of ranibizumab (IVR) combined with SS injections to see the therapeutic effect on her ME and her entire retina function.
We treated this patient with one IVR injection combined with SS injections to see its effect on her ME and her entire retina function. The results demonstrated the efficacy of IVR+SS therapy in reducing ME. The ERG and perimetry results also showed that this treatment could significantly improve this patient's retinal function and visual function.
To our knowledge, this is the first patient who was treated with IVR+SS injection therapy for type II ODV. The result of this case showed rapid decrease in CRT and visual improvement with one-month follow up so far. Considering the strength of evidence, a long time follow-up need to be conducted in this investigation to assess the effect of this treatment method, and more rigorously designed trials are required for assessing the clinical application of this combined therapy to treat type II ODV patients.
Conclusion
In summary, IVR injection and SS injection together could effectively improve the visual acuity and rapidly alleviate the edema in this type II ODV patient.
